Alfuzosin HCl - CAS 81403-68-1
Not Intended for Therapeutic Use. For research use only.
Product Name:
Alfuzosin HCl
Catalog Number:
CAS Number:
Alfuzosin HCl is an alpha1 receptor antagonist used to treat benign prostatic hyperplasia (BPH).
Molecular Weight:
Molecular Formula:
Adrenergic Receptor
Chemical Structure
CAS 81403-68-1 Alfuzosin HCl

Related Adrenergic Receptor Products

CAS 208992-74-9 Fiduxosin hydrochloride

Fiduxosin hydrochloride
(CAS: 208992-74-9)

Fiduxosin hydrochloride is an alpha(1)-adrenoceptor antagonist used for the treatment of benign prostatic hyperplasia.

CAS 118457-14-0 Nebivolol

(CAS: 118457-14-0)

Nebivolol, a highly selective β1-adrenergic receptor inhibitor, has vasodilatory effect so that could be effective against hypertension. It was just withdrawed ...

CAS 51-30-9 Isoprenaline HCl

Isoprenaline HCl
(CAS: 51-30-9)

Isoprenaline is a non-selective beta-adrenergic receptor agonist, used for the treatment of bradycardia and heart block. It would increase cAMP levels and activ...

CAS 65652-44-0 Pirbuterol acetate

Pirbuterol acetate
(CAS: 65652-44-0)

Pirbuterol acetate is a short-acting β2 adrenoreceptor agonist. It has bronchodilating action and is used as a bronchodilator. It is also used in the treatment ...

CAS 158599-53-2 Zoleprodolol

(CAS: 158599-53-2)

Zoleprodolol, an oxadiazol derivative, has been found to be an adrenergic receptor antagonist.

CAS 138908-40-4 CL-316243 sodium

CL-316243 sodium
(CAS: 138908-40-4)

CL-316243 is a highly selective β3-adrenoceptor agonist with EC50 value of 3 nM; > 10000-fold selective over β1 and β2 receptors. CL-316243 can restore the expr...

CAS 63659-18-7 Betaxolol

(CAS: 63659-18-7)

Betaxolol is a selective beta1 adrenergic receptor blocker used in the treatment of hypertension and glaucoma.

CAS 58020-43-2 Hoku-81

(CAS: 58020-43-2)

Hoku 81 is a bronchodilator, and one of the metabolites of tulobuterol.

CAS 72795-01-8 ICI 118551 hydrochloride

ICI 118551 hydrochloride
(CAS: 72795-01-8)

ICI 118551 hydrochloride is a highly selective β2 adrenergic antagonist (Ki values are 1.2, 120 and 257 nM for β2, β1 and β3 receptors respectively), inhibited ...

(CAS: 1198790-53-2)

This active molecular is a SNDR (serotonin-norepinephrine-dopamine reuptake) inhibitor It was originated by Bristol-Myers Squibb for the treatment of major depr...

CAS 59-97-2 Tolazoline HCl

Tolazoline HCl
(CAS: 59-97-2)

Tolazoline is a non-selective competitive α-adrenergic receptor antagonist.

Olodaterol Hydrochloride
(CAS: 869477-96-3)

Olodaterol is an ultra-long-acting β adrenoreceptor agonist. It can be used as an inhalation for treating patients with chronic obstructive pulmonary disease (C...

CAS 70024-40-7 Terazosin HCl

Terazosin HCl
(CAS: 70024-40-7)

Terazosin is a selective alpha 1 antagonist used for treatment of symptoms of an enlarged prostate (BPH).

CAS 86347-14-0 Medetomidine

(CAS: 86347-14-0)

Medetomidine is a potent, highly selective α2-adrenoceptor agonist, which Ki values are 1.08 and 1750 nM for α2- and α1-adrenoceptors respectively. It is often ...

CAS 23031-25-6 Terbutaline

(CAS: 23031-25-6)

Terbutaline, also called as Bronclyn, as a fast-acting bronchodilator it is a β2 adrenergic receptor agonist used to treat asthma and premature labor.

CAS 1218-35-5 Xylometazoline HCl

Xylometazoline HCl
(CAS: 1218-35-5)

Xylometazoline is an α-adrenoceptor agonist commonly used as nasal decongestant, exhibits highest potency at α2B-adrenoceptor subtype with EC50 of 99 μM.

CAS 223673-61-8 Mirabegron

(CAS: 223673-61-8)

Mirabegron (formerly YM-178, trade name Myrbetriq) is a drug for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved in th...

CAS 26921-17-5 Timolol Maleate

Timolol Maleate
(CAS: 26921-17-5)

Timolol Maleate is a non-selective, beta-adrenergic receptor antagonist for β1/β2 with Ki of 1.97 nM/2.0 nM.

CAS 116209-55-3 Levobetaxolol HCl

Levobetaxolol HCl
(CAS: 116209-55-3)

Levobetaxolol exhibits a higher affinity at cloned human β1 and β2 receptors with Ki value of 0.76 nM and 32.6 nM, respectively.

CAS 65-28-1 Phentolamine Mesylate

Phentolamine Mesylate
(CAS: 65-28-1)

Phentolamine Mesylate is a nonselective alpha-adrenergic antagonist with IC50 of 0.1 μM.

Reference Reading

1.Kinetic Spectrophotometric Methods for the Determination of Alfuzosin Hydrochloride in Bulk and Pharmaceutical Formulations1
Salma A. AlTamimi, Fatma A. Aly, and Adibah M. Almutairi. Journal of Analytical Chemistry, 2013, Vol. 68, No. 4, pp. 313–320
The aim of the present work was to develop simple and sensitive kinetic spectrophotometric methods for the determination of alfuzosin HCl in bulk and in its pharmaceutical preparations using alkaline potassium permanganate as an oxidizing agent. The methods involve determination of alfuzosin HCl by kinetic studies of its oxidation at room temperature for a fixed time of 15 min. The absorbance of the colored manganate ions was measured at 610 nm. Alternatively, the decrease in the absorbance of permanganate upon addition of the studied drug was also measured at 525 nm. The methods were successfully applied to the determination of this drug in its dosage forms.
2.Alfuzosin: a clinically uroselective a1-blocker
Klaus Hofner, Udo Jonas. World J Urol (2002) 19: 405–412
Recently, a once-daily (o.d.) formulation of alfuzosin has been developed to improve the treatment compliance and optimise the pharmacokinetic coverage over a 24-h period. To achieve these goals, an innovative extended-release formulation, based on the Geomatrix technology(Geomatrix is a registered trademark of Jagotec AG, a member of SkyePharma Group of Companies), was used. It consists of a white hydrophilic active matrix core containing alfuzosin and two yellow inert layers, one swellable and one erodible, whose functions are to control the hydration and swelling rate of the core, leading to a controlled release of alfuzosin over the dosing interval (Fig. 3). As aqueous fluids progressively penetrate the matrix core, alfuzosin is released through a process of diffusion. Simultaneously, the swellable layer swells at a predetermined rate, increasing the surface area and the volume of the tablet to permit a slow and constant release of alfuzosin in the upper part of the digestive tract. Finally, the erodible layer dissolves with time in the lower part of the digestive tract, which allows a constant dissolution rate of alfuzosin to be maintained as the concentration decreases in the active matrix core.
3.The efficacy of Alfuzosin treatment in patients with prostatism
M. Murad Basar, Ali Atan, Osmanzergin & Mslm Yldz. International Urology and Nephrology 33: 493–497, 2001
The tone of the smooth muscle of the prostate, bladder neck and prostatic urethra is regulated by sympathetic innervation via alpha-1 adrenoceptors. Alpha-1 adrenoceptor blockers decrease the tone of the smooth muscle in the prostatic stroma, prostatic capsule, bladder neck and prostatic urethra, resulting in improving irritative and obstructive symptoms of BPH and increasing urine flow rate. Caine et al. first reported the therapeutic application of the alpha blockage for the treatment of BPH. Although Kirby et al. claimed that symptomatic improvement is generally evident in 60 to 80% of patients receiving alpha adrenocpetor blocker treatment and improvement in symptoms and urodynamic parameters are observed within 2 to 4 weeks after the treatment, Jardin et al. reported that clinical improvement with alfuzosin treatment was apparent after 6 weeks whereas peak flow rate increased and postvoiding residual urine volume decreased by 6 months. Buzelin et al. found that improvement in symptoms was significant after 1 month of the treatment and continued to improve further between weeks 4 and 12 of alfuzosin treatment. In the present study, symptomatic improvement initiated in the 2nd week of the treatment, reaching its maximum level in the 6th week whereas improvement in urodynamic parameters was obtained later than symptomatic improvement.
4.Effects of alfuzosin with methylprednisolone for spontaneous expulsion and pain control of lower ureteral stone
Eu Chang Hwang • In Sang Hwang • Ho Song Yu • Sun-Ouck Kim. Urol Res (2012) 40:605–609
Compared to tamsulosin, alfuzosin exhibits no pharmacological uroselectivity for any of the a1 subtypes (a1A, a1B, and a1D), however, alfuzosin has the lack of adverse effect and blood pressure changes, it has been claimed to be uroselective drug. Thus, it is expected to have the same effect in promoting the spontaneous stone passage. However, this is unclear, given the paucity of studies to date. Also, studies concerning the influence of corticosteroids on stone passage have mainly involved combinations with tamsulosin. Therefore, we investigated the effect of combination therapy with alfuzosin and methylprednisolone on spontaneous passage of lower ureteral stones.